Physician profile
John J Luckey
NPI 1629230768
$1,832.48
in general payments reported to CMS, 2019-2025
27 companies · $163 in 2025
The $163 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $315 · 2020: $236 · 2021: $405 · 2022: $252 · 2023: $252 · 2024: $210 · 2025: $163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $624.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $624.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $400.54 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $152.45 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $129.38 | 2019-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $114.80 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Abbvie INC. | $95.18 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $70.17 | 2019-2023 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $64.22 | 2020-2022 | |
| Abbott Laboratories | $62.67 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $61.11 | 2020-2023 | Eliquis |
| Glaxosmithkline, LLC. | $58.79 | 2019-2025 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.30 | 2019-2023 | |
| Amarin Pharma, INC. | $56.21 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $55.40 | 2022-2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $51.32 | 2019-2024 | Spravato |
| Xeris Pharmaceuticals, INC. | $50.11 | 2021-2024 | Gvoke Hypopen |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $49.98 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $48.18 | 2020-2021 | |
| Mylan Specialty L.P. | $44.72 | 2020-2024 | Yupelri |
| Merck Sharp & Dohme LLC | $40.57 | 2019-2021 | |
| Allergan, INC. | $34.32 | 2019-2020 | |
| Amgen INC. | $31.80 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.80 | 2024 | |
| Dexcom, INC. | $19.55 | 2021 | |
| Medtronic, INC. | $17.27 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $15.61 | 2023 | Seglentis |
| Idorsia Pharmaceuticals US INC | $15.40 | 2023 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $13.63 | 2024 | Ajovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Luckey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.